Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- The Pharma Gospel of Praise
Philip Carrigan
Partner, Optia Partners
philip@optiapartners.com
September 27, 2010
- Daiichi Sankyo Wins Appellate Court Litigation against Mylan
September 27, 2010
- Torisel Ensures Good Compliance with IV Infusion Once a Week: Prof. Horie
September 27, 2010
- Re-Pricing Rule to Be Included in Chuikyo Agenda: Mr Yoshida
September 27, 2010
- Actemra to Change Paradigm for Treatment of RA: Chugai
September 27, 2010
- Int'l Harmonization Conference to Be Created on Drug-Device Combination Products
September 27, 2010
- All-Patients Post-Marketing Investigation on Avastin Finished
September 27, 2010
- Korosho to Support Development of First-in-Class Drugs
September 27, 2010
- Use of Robot in Prostatectomy to Be Approved as Senshin-iryo
September 27, 2010
- Toyobo to Strengthen Bulk Manufacturing & Contract R&D for Biopharmaceuticals
September 27, 2010
- 29 Ex-Korosho Officials Employed by 15 Drug Firms
September 27, 2010
- Mochida Applies for Escitalopram in Japan
September 27, 2010
- LabCorp to Acquire Genzyme Genetics for US$925 Mil. in Cash
September 27, 2010
- Fingolimod Approved in Russia: Novartis
September 27, 2010
- E Keppra to Expand Market for Anti-epileptic Agents: Otsuka, UCB
September 27, 2010
- 5-Aminolevulinic Acid HCl Designated as Orphan Drug
September 27, 2010
- JCR Completes Manufacturing Facility for EPO Biosimilar
September 27, 2010
- Symposiasts Call for Unification of Clinical Research, Trials
September 27, 2010
- Novartis to Keep Weighted Average Invoice Price Unchanged: Mr Mitani
September 27, 2010
- Two GM Mice Lost at Kyowa Kirin's Research Center
September 27, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…